HBM Healthcare Investments AG Share Price
Equities
HBMN
CH0012627250
Investment Management & Fund Operators
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 236.50 CHF | -1.05% |
|
-0.42% | +4.42% |
| 01-06 | HBM Healthcare Investments Expects Higher Nine-month Preliminary Profit | MT |
| 12-15 | HBM Healthcare to Sell Majority Stake in Swixx Biopharma to SK Capital | MT |
| Capitalization | 1.58B 1.97B 1.7B 1.47B 2.74B 179B 2.95B 18.17B 7.17B 85.2B 7.38B 7.23B 311B | P/E ratio 2026 * |
194x | P/E ratio 2027 * | 14.8x |
|---|---|---|---|---|---|
| Enterprise value | 1.58B 1.97B 1.7B 1.47B 2.74B 178B 2.94B 18.15B 7.16B 85.09B 7.37B 7.22B 311B | EV / Sales 2026 * |
45x | EV / Sales 2027 * | 11.6x |
| Free-Float |
80.6% | Yield 2026 * |
3.23% | Yield 2027 * | 3.12% |
| 1 day | -1.05% | ||
| 1 week | -0.42% | ||
| Current month | +4.42% | ||
| 1 month | +7.26% | ||
| 3 months | +17.66% | ||
| 6 months | +44.03% | ||
| Current year | +4.42% |
| 1 week | 225.5 |  | 239 |
| 1 month | 218 | | 239 |
| Current year | 219 | | 239 |
| 1 year | 150 | | 239 |
| 3 years | 135.2 | | 239 |
| 5 years | 135.2 | | 367 |
| 10 years | 91.4 | | 367 |
| Manager | Title | Age | Since |
|---|---|---|---|
Andreas Wicki
CEO | Chief Executive Officer | 66 | 19/02/2012 |
Erwin Troxler
DFI | Director of Finance/CFO | 55 | 31/10/2011 |
Benedikt Suter
SEC | Corporate Secretary | 61 | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 31/05/2009 | |
Rudolf Lanz
BRD | Director/Board Member | 75 | 31/12/2002 |
Mario Giuliani
BRD | Director/Board Member | 53 | 31/12/2011 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.05% | -0.42% | +31.39% | +8.74% | 1.97B | |
| -0.32% | +1.72% | -8.51% | +38.53% | 3.39B | |
| +1.24% | +2.21% | +78.09% | +27.51% | 1.27B | |
| 0.00% | 0.00% | +2.66% | -1.49% | 648M | |
| -1.05% | -1.77% | -17.32% | -11.68% | 488M | |
| -4.44% | -8.51% | -50.57% | -74.25% | 474M | |
| +3.81% | -9.15% | +173.43% | +188.19% | 462M | |
| -2.38% | +0.14% | -4.78% | +58.32% | 389M | |
| 0.00% | 0.00% | -3.59% | -10.79% | 362M | |
| 0.00% | 0.00% | -0.67% | 0.00% | 354M | |
| Average | -0.42% | -1.88% | +20.01% | +22.31% | 981.32M | |
| Weighted average by Cap. | -0.34% | -0.27% | +18.17% | +25.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 35.1M 43.74M 37.7M 32.68M 60.84M 3.97B 65.46M 404M 159M 1.89B 164M 161M 6.91B | 134M 167M 144M 125M 233M 15.19B 251M 1.55B 610M 7.25B 628M 615M 26.47B |
| Net income | 10.2M 12.71M 10.96M 9.5M 17.68M 1.15B 19.02M 117M 46.26M 550M 47.66M 46.68M 2.01B | 110M 136M 118M 102M 190M 12.38B 204M 1.26B 497M 5.91B 512M 501M 21.56B |
| Net Debt | -2M -2.49M -2.15M -1.86M -3.47M -226M -3.73M -23.01M -9.07M -108M -9.35M -9.15M -394M | -20M -24.92M -21.48M -18.62M -34.67M -2.26B -37.3M -230M -90.71M -1.08B -93.45M -91.53M -3.94B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 236.50 CHF | -1.05% | 4,018 |
| 15/01/26 | 239.00 CHF | +2.58% | 11,981 |
| 14/01/26 | 233.00 CHF | 0.00% | 9,078 |
| 13/01/26 | 233.00 CHF | -1.27% | 10,326 |
| 12/01/26 | 236.00 CHF | -0.63% | 3,068 |
Delayed Quote Swiss Exchange, January 16, 2026 at 04:31 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- HBMN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition